+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032- Product Image
HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032- Product Image
Sale

HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 35 Pages
  • November 2023
  • Region: Global
  • Allied Market Research
  • ID: 5237508
UP TO OFF until Jan 30th 2025
Description Jump to:
The HIV drugs market was valued at $32.8 billion in 2022 and is estimated to reach $51.1 billion by 2032, exhibiting a CAGR of 4.5% from 2023 to 2032. Human immunodeficiency virus (HIV) attacks the body’s immune system, leading to complete damage of the system and making the host system susceptible to infection. The virus attacks the CD4 cells, whose primary role is to help the immune system defend against infections, thus destroying the first line of defense of the human body and exposing the person to various infections. HIV is one of the most alarming and widespread diseases globally. The major route of transmission of HIV infection is through unprotected sex, use of contaminated needles, breast milk of HIV-infected mother to child, and infected blood.

Major factors that drive the growth of the global HIV drugs market include rapid advancements in treatment of HIV; rise in number of research regarding HIV drugs; and increase in number of patients suffering from HIV. For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), in 2022, the estimated total number of HIV patients is 2.2 million in Latin America. Furthermore, surge in demand for HIV drugs, increase in number of awareness programs regarding HIV, and rise in number of clinical trials for the development of HIV drugs boost the growth of HIV drugs market.

In addition, increase in target population, rise in diagnosis rate of HIV, and surge in the prevalence of HIV diseases propel the market growth. However, stringent government regulations for the approval and commercialization of HIV drugs are expected to restrict the growth of HIV drugs market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future.

The HIV drugs market is segmented on the basis of medication class, distribution channel, and region. On the basis of medication class, the market is categorized into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, HIV integrase strand transfer inhibitors and others. The multi-class combination drugs segment is further categorized into Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, descovy, dovato and others. The nucleoside reverse transcriptase inhibitors (NRTIs) segment is further categorized into Emtriva, Epivir, Epzicom, Truvada, biktavry and others. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) segment is further categorized into Edurant and others. The protease inhibitors (PIs) segment is further categorized into Aptivus, Kaletra, Lexiva/Telzir, Norvir, Viracept and others. The entry inhibitors segment is further categorized into Selzentry, Fuzeon and Rukobia. The HIV integrase strand transfer inhibitors segment is further categorized into Isentress/Isentress HD, Tivicay, Apretude and Juluca.

On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major players profiled in the report are AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GSK plc (ViiV Healthcare), Johnson & Johnson, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd. These major players have adopted product approval, partnership, and product launch as key developmental strategies to improve the product portfolio of the HIV drugs market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv drugs market analysis from 2022 to 2032 to identify the prevailing hiv drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hiv drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hiv drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Go To Market Strategy
  • Market share analysis of players by products/segments
  • New Product Development/Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Average Selling Price Analysis/Price Point Analysis
  • Brands Share Analysis
  • Criss-cross segment analysis- market size and forecast
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Medication Class

  • Multi-Class Combination Drugs
  • Brand
  • Atripla
  • Complera
  • Prezcobix
  • Stribild
  • Genvoya
  • Odefsey
  • Symtuza
  • Triumeq
  • Descovy
  • Dovato
  • Others
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Brand
  • Emtriva
  • Epivir
  • Epzicom/Kivexa
  • Truvada
  • Biktarvy
  • Others
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Brand
  • Edurant
  • Others
  • Protease Inhibitors (PIs)
  • Brand
  • Aptivus
  • Kaletra
  • Lexiva/Telzir
  • Norvir
  • Viracept
  • Others
  • Entry Inhibitors
  • Brand
  • Selzentry
  • Fuzeon
  • Rukobia
  • HIV Integrase Strand Transfer Inhibitors
  • Brand
  • Isentress/Isentress HD
  • Tivicay
  • Apretude
  • Juluca
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drugs stores and retail pharmacies
  • Online pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Key Market Players
  • Merck & Co., Inc.
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in cases of HIV
3.4.1.2. Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
3.4.1.3. Introduction of generic drugs for HIV
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
3.4.3. Opportunities
3.4.3.1. Increasing number of products in the pipeline
CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Multi-Class Combination Drugs
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Multi-Class Combination Drugs HIV Drugs Market by Brand
4.3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) HIV Drugs Market by Brand
4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) HIV Drugs Market by Brand
4.5. Protease Inhibitors (PIs)
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.5.4. Protease Inhibitors (PIs) HIV Drugs Market by Brand
4.6. Entry Inhibitors
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.6.4. Entry Inhibitors HIV Drugs Market by Brand
4.7. HIV Integrase Strand Transfer Inhibitors
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
4.7.4. HIV Integrase Strand Transfer Inhibitors HIV Drugs Market by Brand
4.8. Others
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market share analysis by country
CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital Pharmacies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Drugs stores and retail pharmacies
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Online pharmacies
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: HIV DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Medication Class
6.2.3. Market size and forecast, by Distribution Channel
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Medication Class
6.2.4.1.2. Market size and forecast, by Distribution Channel
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Medication Class
6.2.4.2.2. Market size and forecast, by Distribution Channel
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Medication Class
6.2.4.3.2. Market size and forecast, by Distribution Channel
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Medication Class
6.3.3. Market size and forecast, by Distribution Channel
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Medication Class
6.3.4.1.2. Market size and forecast, by Distribution Channel
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Medication Class
6.3.4.2.2. Market size and forecast, by Distribution Channel
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Medication Class
6.3.4.3.2. Market size and forecast, by Distribution Channel
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Medication Class
6.3.4.4.2. Market size and forecast, by Distribution Channel
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Medication Class
6.3.4.5.2. Market size and forecast, by Distribution Channel
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Medication Class
6.3.4.6.2. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Medication Class
6.4.3. Market size and forecast, by Distribution Channel
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Medication Class
6.4.4.1.2. Market size and forecast, by Distribution Channel
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Medication Class
6.4.4.2.2. Market size and forecast, by Distribution Channel
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Medication Class
6.4.4.3.2. Market size and forecast, by Distribution Channel
6.4.4.4. India
6.4.4.4.1. Market size and forecast, by Medication Class
6.4.4.4.2. Market size and forecast, by Distribution Channel
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Medication Class
6.4.4.5.2. Market size and forecast, by Distribution Channel
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Medication Class
6.4.4.6.2. Market size and forecast, by Distribution Channel
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Medication Class
6.5.3. Market size and forecast, by Distribution Channel
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Medication Class
6.5.4.1.2. Market size and forecast, by Distribution Channel
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Medication Class
6.5.4.2.2. Market size and forecast, by Distribution Channel
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Medication Class
6.5.4.3.2. Market size and forecast, by Distribution Channel
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Medication Class
6.5.4.4.2. Market size and forecast, by Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Merck & Co., Inc.
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Gilead Sciences, Inc.
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. GlaxoSmithKline plc
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Johnson & Johnson
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. F. Hoffmann-La Roche Ltd.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. Teva Pharmaceutical Industries Ltd.
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Cipla Ltd.
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Bristol-Myers Squibb Company
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
List of Tables
Table 01. Global HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 02. HIV Drugs Market for Multi-Class Combination Drugs, by Region, 2022-2032 ($Million)
Table 03. Global Multi-Class Combination Drugs HIV Drugs Market, by Brand, 2022-2032 ($Million)
Table 04. HIV Drugs Market for Nucleoside Reverse Transcriptase Inhibitors (Nrtis), by Region, 2022-2032 ($Million)
Table 05. Global Nucleoside Reverse Transcriptase Inhibitors (Nrtis) HIV Drugs Market, by Brand, 2022-2032 ($Million)
Table 06. HIV Drugs Market for Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), by Region, 2022-2032 ($Million)
Table 07. Global Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis) HIV Drugs Market, by Brand, 2022-2032 ($Million)
Table 08. HIV Drugs Market for Protease Inhibitors (Pis), by Region, 2022-2032 ($Million)
Table 09. Global Protease Inhibitors (Pis) HIV Drugs Market, by Brand, 2022-2032 ($Million)
Table 10. HIV Drugs Market for Entry Inhibitors, by Region, 2022-2032 ($Million)
Table 11. Global Entry Inhibitors HIV Drugs Market, by Brand, 2022-2032 ($Million)
Table 12. HIV Drugs Market for HIV Integrase Strand Transfer Inhibitors, by Region, 2022-2032 ($Million)
Table 13. Global HIV Integrase Strand Transfer Inhibitors HIV Drugs Market, by Brand, 2022-2032 ($Million)
Table 14. HIV Drugs Market for Others, by Region, 2022-2032 ($Million)
Table 15. Global HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 16. HIV Drugs Market for Hospital Pharmacies, by Region, 2022-2032 ($Million)
Table 17. HIV Drugs Market for Drugs Stores and Retail Pharmacies, by Region, 2022-2032 ($Million)
Table 18. HIV Drugs Market for Online Pharmacies, by Region, 2022-2032 ($Million)
Table 19. HIV Drugs Market, by Region, 2022-2032 ($Million)
Table 20. North America HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 21. North America HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 22. North America HIV Drugs Market, by Country, 2022-2032 ($Million)
Table 23. U.S. HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 24. U.S. HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 25. Canada HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 26. Canada HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 27. Mexico HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 28. Mexico HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 29. Europe HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 30. Europe HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 31. Europe HIV Drugs Market, by Country, 2022-2032 ($Million)
Table 32. Germany HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 33. Germany HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 34. France HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 35. France HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 36. UK HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 37. UK HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 38. Italy HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 39. Italy HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 40. Spain HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 41. Spain HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 42. Rest of Europe HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 43. Rest of Europe HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 44. Asia-Pacific HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 45. Asia-Pacific HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 46. Asia-Pacific HIV Drugs Market, by Country, 2022-2032 ($Million)
Table 47. Japan HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 48. Japan HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 49. China HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 50. China HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 51. Australia HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 52. Australia HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 53. India HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 54. India HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 55. South Korea HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 56. South Korea HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 57. Rest of Asia-Pacific HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 58. Rest of Asia-Pacific HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 59. LAMEA HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 60. LAMEA HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 61. LAMEA HIV Drugs Market, by Country, 2022-2032 ($Million)
Table 62. Brazil HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 63. Brazil HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 64. Saudi Arabia HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 65. Saudi Arabia HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 66. South Africa HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 67. South Africa HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 68. Rest of LAMEA HIV Drugs Market, by Medication Class, 2022-2032 ($Million)
Table 69. Rest of LAMEA HIV Drugs Market, by Distribution Channel, 2022-2032 ($Million)
Table 70. Abbvie Inc.: Key Executives
Table 71. Abbvie Inc.: Company Snapshot
Table 72. Abbvie Inc.: Product Segments
Table 73. Abbvie Inc.: Product Portfolio
Table 74. Merck & Co. Inc.: Key Executives
Table 75. Merck & Co. Inc.: Company Snapshot
Table 76. Merck & Co. Inc.: Product Segments
Table 77. Merck & Co. Inc.: Product Portfolio
Table 78. Merck & Co. Inc.: Key Strategies
Table 79. Boehringer Ingelheim International GmbH: Key Executives
Table 80. Boehringer Ingelheim International GmbH: Company Snapshot
Table 81. Boehringer Ingelheim International GmbH: Product Segments
Table 82. Boehringer Ingelheim International GmbH: Product Portfolio
Table 83. Gilead Sciences, Inc.: Key Executives
Table 84. Gilead Sciences, Inc.: Company Snapshot
Table 85. Gilead Sciences, Inc.: Product Segments
Table 86. Gilead Sciences, Inc.: Product Portfolio
Table 87. Gilead Sciences, Inc.: Key Strategies
Table 88. GlaxoSmithKline PLC: Key Executives
Table 89. GlaxoSmithKline PLC: Company Snapshot
Table 90. GlaxoSmithKline PLC: Product Segments
Table 91. GlaxoSmithKline PLC: Product Portfolio
Table 92. GlaxoSmithKline PLC: Key Strategies
Table 93. Johnson & Johnson: Key Executives
Table 94. Johnson & Johnson: Company Snapshot
Table 95. Johnson & Johnson: Product Segments
Table 96. Johnson & Johnson: Product Portfolio
Table 97. Johnson & Johnson: Key Strategies
Table 98. F. Hoffmann-La Roche Ltd.: Key Executives
Table 99. F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 100. F. Hoffmann-La Roche Ltd.: Product Segments
Table 101. F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 102. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 103. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 104. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 105. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 106. Cipla Ltd.: Key Executives
Table 107. Cipla Ltd.: Company Snapshot
Table 108. Cipla Ltd.: Product Segments
Table 109. Cipla Ltd.: Product Portfolio
Table 110. Bristol-Myers Squibb Company: Key Executives
Table 111. Bristol-Myers Squibb Company: Company Snapshot
Table 112. Bristol-Myers Squibb Company: Product Segments
Table 113. Bristol-Myers Squibb Company: Product Portfolio
List of Figures
Figure 01. HIV Drugs Market, 2022-2032
Figure 02. Segmentation of HIV Drugs Market,2022-2032
Figure 03. Top Impacting Factors in HIV Drugs Market (2022 to 2032)
Figure 04. Top Investment Pockets in HIV Drugs Market (2023-2032)
Figure 05. Low Bargaining Power of Suppliers
Figure 06. Low Threat of New Entrants
Figure 07. Low Threat of Substitutes
Figure 08. Low Intensity of Rivalry
Figure 09. Low Bargaining Power of Buyers
Figure 10. Global HIV Drugs Market:Drivers, Restraints and Opportunities
Figure 11. HIV Drugs Market, by Medication Class, 2022 and 2032(%)
Figure 12. Comparative Share Analysis of HIV Drugs Market for Multi-Class Combination Drugs, by Country 2022 and 2032(%)
Figure 13. Comparative Share Analysis of HIV Drugs Market for Nucleoside Reverse Transcriptase Inhibitors (Nrtis), by Country 2022 and 2032(%)
Figure 14. Comparative Share Analysis of HIV Drugs Market for Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), by Country 2022 and 2032(%)
Figure 15. Comparative Share Analysis of HIV Drugs Market for Protease Inhibitors (Pis), by Country 2022 and 2032(%)
Figure 16. Comparative Share Analysis of HIV Drugs Market for Entry Inhibitors, by Country 2022 and 2032(%)
Figure 17. Comparative Share Analysis of HIV Drugs Market for HIV Integrase Strand Transfer Inhibitors, by Country 2022 and 2032(%)
Figure 18. Comparative Share Analysis of HIV Drugs Market for Others, by Country 2022 and 2032(%)
Figure 19. HIV Drugs Market, by Distribution Channel, 2022 and 2032(%)
Figure 20. Comparative Share Analysis of HIV Drugs Market for Hospital Pharmacies, by Country 2022 and 2032(%)
Figure 21. Comparative Share Analysis of HIV Drugs Market for Drugs Stores and Retail Pharmacies, by Country 2022 and 2032(%)
Figure 22. Comparative Share Analysis of HIV Drugs Market for Online Pharmacies, by Country 2022 and 2032(%)
Figure 23. HIV Drugs Market by Region, 2022 and 2032(%)
Figure 24. U.S. HIV Drugs Market, 2022-2032 ($Million)
Figure 25. Canada HIV Drugs Market, 2022-2032 ($Million)
Figure 26. Mexico HIV Drugs Market, 2022-2032 ($Million)
Figure 27. Germany HIV Drugs Market, 2022-2032 ($Million)
Figure 28. France HIV Drugs Market, 2022-2032 ($Million)
Figure 29. UK HIV Drugs Market, 2022-2032 ($Million)
Figure 30. Italy HIV Drugs Market, 2022-2032 ($Million)
Figure 31. Spain HIV Drugs Market, 2022-2032 ($Million)
Figure 32. Rest of Europe HIV Drugs Market, 2022-2032 ($Million)
Figure 33. Japan HIV Drugs Market, 2022-2032 ($Million)
Figure 34. China HIV Drugs Market, 2022-2032 ($Million)
Figure 35. Australia HIV Drugs Market, 2022-2032 ($Million)
Figure 36. India HIV Drugs Market, 2022-2032 ($Million)
Figure 37. South Korea HIV Drugs Market, 2022-2032 ($Million)
Figure 38. Rest of Asia-Pacific HIV Drugs Market, 2022-2032 ($Million)
Figure 39. Brazil HIV Drugs Market, 2022-2032 ($Million)
Figure 40. Saudi Arabia HIV Drugs Market, 2022-2032 ($Million)
Figure 41. South Africa HIV Drugs Market, 2022-2032 ($Million)
Figure 42. Rest of LAMEA HIV Drugs Market, 2022-2032 ($Million)
Figure 43. Product Mapping of Top 10 Players
Figure 44. Competitive Dashboard
Figure 45. Competitive Heatmap: HIV Drugs Market
Figure 46. Top Player Positioning, 2022
Figure 47. Abbvie Inc.: Net Revenue, 2020-2022 ($Million)
Figure 48. Abbvie Inc.: Revenue Share by Segment, 2022 (%)
Figure 49. Abbvie Inc.: Revenue Share by Region, 2022 (%)
Figure 50. Merck & Co. Inc.: Net Revenue, 2020-2022 ($Million)
Figure 51. Merck & Co. Inc.: Revenue Share by Segment, 2022 (%)
Figure 52. Merck & Co. Inc.: Revenue Share by Region, 2022 (%)
Figure 53. Boehringer Ingelheim International GmbH: Net Sales, 2020-2022 ($Million)
Figure 54. Boehringer Ingelheim International GmbH: Revenue Share by Segment, 2022 (%)
Figure 55. Boehringer Ingelheim International GmbH: Revenue Share by Region, 2022 (%)
Figure 56. Gilead Sciences, Inc.: Net Revenue, 2020-2022 ($Million)
Figure 57. GlaxoSmithKline PLC: Net Sales, 2020-2022 ($Million)
Figure 58. GlaxoSmithKline PLC: Revenue Share by Segment, 2022 (%)
Figure 59. GlaxoSmithKline PLC: Revenue Share by Region, 2022 (%)
Figure 60. Johnson & Johnson: Net Sales, 2020-2022 ($Million)
Figure 61. Johnson & Johnson: Revenue Share by Segment, 2022 (%)
Figure 62. Johnson & Johnson: Revenue Share by Region, 2022 (%)
Figure 63. F. Hoffmann-La Roche Ltd.: Sales Revenue, 2020-2022 ($Million)
Figure 64. F. Hoffmann-La Roche Ltd.: Revenue Share by Segment, 2022 (%)
Figure 65. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2020-2022 ($Million)
Figure 66. Teva Pharmaceutical Industries Ltd.: Revenue Share by Region, 2022 (%)
Figure 67. Cipla Ltd.: Sales Revenue, 2020-2022 ($Million)
Figure 68. Cipla Ltd.: Revenue Share by Segment, 2022 (%)
Figure 69. Cipla Ltd.: Revenue Share by Region, 2022 (%)
Figure 70. Bristol-Myers Squibb Company: Net Sales, 2020-2022 ($Million)
Figure 71. Bristol-Myers Squibb Company: Revenue Share by Region, 2022 (%)

Companies Mentioned

  • Merck & Co., Inc.
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

HIV Drugs Global Market Report 2024 - Product Image

HIV Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
North America HIV Drugs Market Report by Drug Class, Distribution Channel, and Country 2024-2032 - Product Image

North America HIV Drugs Market Report by Drug Class, Distribution Channel, and Country 2024-2032

  • Report
  • 121 Pages
  • North America
From
HIV Drugs - Global Strategic Business Report - Product Image

HIV Drugs - Global Strategic Business Report

  • Report
  • 164 Pages
  • Global
From
HIV Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

HIV Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
HIV Drugs Market Analysis & Forecast to 2024-2034 - Product Image

HIV Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.